High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial
- 1 August 2016
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 23 (5) , 675-685
Abstract
Erythropoietin (EPO) is a part of an endogenous neuroprotective system in the brain and may address pathophysiological mechanisms in progressive multiple sclerosis (MS). To evaluate a treatment effect of EPO on progressive MS. This was a single-center, randomized, double-blind, placebo-controlled phase 2 trial, in which 52 patients with secondary or primary progressive MS were allocated to treatment with recombinant EPO (48,000 IU) or placebo, administered intravenously 17 times during 24 weeks. Patients had an Expanded Disability Status Score (EDSS) from 4 to 6.5 and clinical progression without relapses in the 2 preceding years. The primary outcome was the change in a composite measure of maximum gait distance, hand dexterity, and cognition from baseline to 24 weeks. A total of 50 patients completed the study. Venesection was performed often but no thromboembolic events occurred. We found no difference in the primary outcome between the EPO and the placebo group using the intention-to-treat principle (p = 0.22). None of the secondary outcomes, neither clinical nor magnetic resonance imaging (MRI) measures showed any significant differences. This study provides class II evidence that treatment with high-dose EPO is not an effective treatment in patients with moderately advanced progressive MS.Keywords
This publication has 38 references indexed in Scilit:
- Clinical trials in progressive multiple sclerosis: lessons learned and future perspectivesThe Lancet Neurology, 2015
- Pathological mechanisms in progressive multiple sclerosisThe Lancet Neurology, 2015
- Defining the clinical course of multiple sclerosisNeurology, 2014
- Therapeutic Efficacy of Erythropoietin in Experimental Autoimmune Encephalomyelitis in Mice, a Model of Multiple Sclerosis2013
- Exploring recombinant human erythropoietin in chronic progressive multiple sclerosisBrain, 2007
- Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”Annals of Neurology, 2005
- Emerging biological roles for erythropoietin in the nervous systemNature Reviews Neuroscience, 2005
- Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon β1aAnnals of Neurology, 2003
- Relapses and Progression of Disability in Multiple SclerosisNew England Journal of Medicine, 2000
- Rating neurologic impairment in multiple sclerosisNeurology, 1983